Sevoflurane, sold under the brand name Sevorane, among others, is a sweet-smelling, nonflammable, highly fluorinated methyl isopropyl ether used as an inhalational anaesthetic for induction and maintenance of general anesthesia. After desflurane, it is the volatile anesthetic with the fastest onset. [8] .

七氟醚 （英語： Sevoflurane）為一種 非易燃 、氣味香甜的鹵代醚麻醉藥，可以誘導和維持 全身麻醉。 其藥力起效和消退速度甚快，僅次於 地氟醚 [1]。 本藥通常與 笑氣 和 氧氣 混合後，以吸入形式施用。 七氟醚的安全記錄良好 [2]，但可能對嬰幼兒構成 神經毒性，及在罕見情況下導致類似 氟烷 的 肝毒性 （英语：Hepatotoxicity） 問題，引起了醫學界的關注 [2]。 由於對氣道 粘膜 的刺激性較低，七氟醚成為了誘導麻醉的首選用藥。 七氟醚的發現者為罗斯·特雷尔（Robert …

2024年2月20日 · Easy-to-read patient leaflet for Sevoflurane. Includes indications, proper use, special instructions, precautions, and possible side effects.

2023年6月5日 · Sevoflurane is a volatile anesthetic that provides hypnosis, amnesia, analgesia, akinesia, and autonomic blockade during surgical and procedural interventions. This activity describes the mode of action of sevoflurane and highlights the role of the interprofessional team in the safe administration of anesthesia.

2025年4月1日 · Inhaled sevoflurane is used to cause general anesthesia (loss of consciousness) before and during surgery. It belongs to the group of medicines known as general anesthetics.

2025年1月7日 · Sevoflurane is a volatile halogenated general anaesthetic that has a minimum alveolar concentration (MAC) value ranging from 1.4% to 3.3%. It alters the activity of fast …

Sevoflurane is a inhalation anaesthetic agent used for induction and maintenance of general anesthesia during surgical procedures.

2025年2月19日 · What Is Sevoflurane and How Does It Work? Sevoflurane is a prescription medicine used as anesthesia during surgery. What Are Dosages of Sevoflurane? Adult and …

2024年12月24日 · 七氟烷（又名七氟醚，Sevoflurane）是一种非易燃、气味香甜的卤代醚麻醉药，可以诱导和维持全身麻醉，其药力起效和消退速度甚快，仅次于地氟醚。

Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia. It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition coefficient. Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 1996.